SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (4666)7/1/1998 12:19:00 AM
From: John Metcalf   of 6136
 
One big question:

Why did Merck sell its stake in DuPont-Merck to DD, leaving DuPont with Sustiva?

As Margie pointed out, there is a study showing Sustiva lowers blood concentrations of Crixivan (but raises concs of Viracept). So the Sustiva-Crix combo may not be viable for Merck.

But will Sustiva replace Crix and Viracept and the other PI's? Obviously, Merck doesn't think so, or wouldn't have sold it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News